CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $) In Millions, unless otherwise specified	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash Flows From Operating Activities:
Net Earnings	$ 1,845	$ 1,577
Adjustments to reconcile net earnings to net cash provided by operating activities:
Net earnings attributable to noncontrolling interest	(8)	(542)
Depreciation and amortization, net	582	482
Deferred income taxes	(409)	(737)
Stock-based compensation	140	108
Impairment charges	6	2,118
Proceeds from Amylin diabetes collaboration		3,570
Other adjustments	(11)	21
Changes in operating assets and liabilities:
Receivables	(563)	643
Inventories	(8)	(135)
Accounts payable	301	(321)
Deferred income	702	100
Income taxes payable	128	82
Other	(570)	(861)
Net Cash Provided by Operating Activities	2,135	6,105
Cash Flows From Investing Activities:
Sale and maturities of marketable securities	1,520	4,384
Purchases of marketable securities	(1,448)	(3,501)
Additions to property, plant and equipment and capitalized software	(337)	(373)
Sales of businesses and other investing activities	8	16
Purchase of businesses, net of cash acquired		(7,530)
Net Cash Provided by/(Used in) Investing Activities	(257)	(7,004)
Cash Flows From Financing Activities:
Short-term borrowings, net	488	20
Proceeds from issuance of long-term debt	12	1,950
Long-term debt repayments	(597)	(2,108)
Interest rate swap terminations		2
Issuance of common stock	483	397
Common stock repurchases	(433)	(1,911)
Dividends	(1,732)	(1,725)
Net Cash Used in Financing Activities	(1,779)	(3,375)
Effect of Exchange Rates on Cash and Cash Equivalents	16	1
Increase/(Decrease) in Cash and Cash Equivalents	115	(4,273)
Cash and Cash Equivalents at Beginning of Period	1,656	5,776
Cash and Cash Equivalents at End of Period	$ 1,771	$ 1,503